In the political and policy arena, respondents see implementation of the Inflation Recovery Act as having a major effect this year.
Healthcare technology is teeming with possibilities for improving the cost and delivery of healthcare. Precision medicine, artificial intelligence, prescription digital therapeutics — they are all being talked about as powerful waves that will shape the future contours of U.S. healthcare.
But as far as having an effect this year, remote are technologies was the top pick among the respondents to the Managed Healthcare Executive® annual State of the Industry survey. A solid majority — 56% — of the approximately 450 respondents to the survey indicated that remote care technology would be among the healthcare technology developments to have the biggest effect on the cost and delivery of healthcare in 2023.
One-third (33%) of the respondents picked interoperability. A similar proportion (32%) picked prescription digital therapeutics. The respondents were instructed to pick more than one of the choices, which also included gene therapy,precision medicine and artificial intelligence
In the policy and political arena, implementation of the healthcare provisions of the Inflation Recovery Act was the top pick for making a splash this year: 54% of the respondents picked it in response a question which policy and political developments will have the biggest effect this year. Perhaps the most important provision of the law is the one that empowers CMS to negotiate drug prices. According to a timeline that CMS issued last week, CMS will publish a list of the first 10 drugs for which it will negotiate a price on Sept. 1, 2023, but it won’t be until 2026 that the negotiated prices will go into effect.
A little more than one-third (35%) respondents picked the end of the COVID-19 public health emergency as having a large effect this year and less than one-third (31%) picked the end of continuous Medicaid enrollment.
The survey was conducted online in November and early December. Medical Economics® assisted with its distribution,
In this second part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein spoke with CeCi Connolly and Margaret "Meg" Murray about Medicare Advantage utilization and challenges, highlighting proposed CMS payment cuts and prior authorization issues.
Listen
In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and CeCi Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.
Listen
FDA Approves Combination Therapy for Pulmonary Arterial Hypertension
March 26th 2024J&J’s Opsynvi is single-tablet combination of macitentan, an endothelin receptor antagonist, and tadalafil, a PDE5 inhibitor. It will be priced on parity with Opsumit, which is also a J&J product to treat patients with PAH.
Read More